{"id":"vancomycin-intermittent-dosing-interval","safety":{"commonSideEffects":[{"rate":"5-25%","effect":"Nephrotoxicity"},{"rate":"1-5%","effect":"Ototoxicity"},{"rate":"10-15%","effect":"Red man syndrome (flushing, pruritus)"},{"rate":"5-10%","effect":"Phlebitis at infusion site"},{"rate":"1-5%","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin works by preventing cross-linking of peptidoglycan strands in the bacterial cell wall, leading to cell wall instability and bacterial death. The intermittent dosing interval refers to the clinical dosing schedule (typically every 8-12 hours) rather than a novel mechanism, optimizing drug exposure and reducing nephrotoxicity while maintaining efficacy against susceptible gram-positive organisms.","oneSentence":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:13.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA)"},{"name":"Clostridium difficile-associated diarrhea"},{"name":"Endocarditis"},{"name":"Meningitis caused by susceptible organisms"}]},"trialDetails":[{"nctId":"NCT05823116","phase":"PHASE4","title":"Continuous vs. Intermittent Infusion Vancomycin","status":"COMPLETED","sponsor":"Aaron Cook","startDate":"2023-05-22","conditions":"Vancomycin","enrollment":37},{"nctId":"NCT05770622","phase":"PHASE4","title":"Improving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2)","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-11-10","conditions":"Sepsis, Infections, Bacteremia","enrollment":40},{"nctId":"NCT03909698","phase":"","title":"Antibiotic Dosing in Patients on Intermittent Hemodialysis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-09-15","conditions":"Kidney Failure, Chronic, Antibiotics, Hemodialysis","enrollment":150},{"nctId":"NCT01786161","phase":"PHASE4","title":"Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2013-09","conditions":"MRSA - Methicillin Resistant Staphylococcus Aureus Infection","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vancomycin intermittent dosing interval","genericName":"Vancomycin intermittent dosing interval","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Serious gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile-associated diarrhea, Endocarditis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}